Comparative CNS Pharmacology of the Bruton’s Tyrosine Kinase (BTK) Inhibitor Tolebrutinib Versus Other BTK Inhibitor Candidates for Treating Multiple Sclerosis

Timothy J. Turner,Priscilla Brun,Ross Gruber,Dimitry Ofengeim

DOI: https://doi.org/10.1101/2024.03.25.586667

2024-03-29

Abstract:Tolebrutinib is a covalent BTK inhibitor designed and selected for potency and CNS exposure to optimize impact on BTK-dependent signaling in CNS-resident cells. We applied a translational approach to evaluate three BTK inhibitors in Phase 3 clinical development in MS with respect to their relative potency to block BTK-dependent signaling and exposure in the CNS, employing kinase, cellular activation assays, and pharmacokinetic sampling of cerebrospinal fluid (CSF) in the non-human primate cynomolgus to estimate the ability of these candidates (evobrutinib, fenebrutinib, and tolebrutinib) to block BTK-dependent signaling inside the CNS. kinase assays demonstrated that tolebrutinib reacted with BTK 65-times faster than evobrutinib, while fenebrutinib, a classical reversible antagonist with a K value of 4.7 nM and slow off-rate (1.54 x 10 s ), also had an association rate 1760-fold slower (3.28 x 10 M * s ). Estimates of cellular potency were largely consistent with the kinase assays, with an estimated IC50 of 0.7 nM for tolebrutinib against 34.5 nM for evobrutinib and 2.9 nM for fenebrutinib. We then observed that evobrutinib, fenebrutinib, and tolebrutinib achieved similar levels of exposure in non-human primate CSF after oral doses of 10 mg/kg. However, tolebrutinib CSF exposure (4.8 ng/mL) (kp,uu CSF=0.40) exceeded the IC90 (the estimated concentration inhibiting 90% of kinase activity) value, while evobrutinib (3.2 ng/mL) (kp,uu CSF=0.13) and fenebrutinib (12.9 ng/mL) (kp,uu CSF=0.15) failed to reach the estimated IC90 values. We conclude that tolebrutinib is the only candidate that attained relevant CSF exposure in non-human primates.

Pharmacology and Toxicology

What problem does this paper attempt to address?

The problem that this paper attempts to solve is to evaluate the relative potency and central nervous system (CNS) penetration ability of three BTK (Bruton’s tyrosine kinase) inhibitors - Tolebrutinib, Evobrutinib and Fenebrutinib in the treatment of multiple sclerosis (MS). Specifically, the study aims to answer the following key questions:

1. **Relative potency of BTK inhibitors**: Compare the potency of these three BTK inhibitors in blocking BTK - dependent signal transduction by in vitro kinase activity assays, cell activation experiments and other methods.

2. **CNS penetration ability**: Evaluate whether these inhibitors can effectively cross the blood - brain barrier (BBB) and reach sufficient concentrations in the CNS to inhibit BTK activity.

3. **Prediction of clinical efficacy**: Based on the pharmacokinetic data in non - human primate models, predict the potential efficacy of these candidate drugs in humans, especially whether they can reach the concentration required to inhibit 90% kinase activity (IC90) in the CNS.

### Main conclusions

- **Potency and speed of Tolebrutinib**: Tolebrutinib showed the highest potency in in vitro kinase activity assays, and its reaction rate was 65 times faster than that of Evobrutinib and 1760 times faster than that of Fenebrutinib.

- **CNS penetration ability**: The exposure of Tolebrutinib in the cerebrospinal fluid (CSF) of non - human primates reached the IC90 value, while Evobrutinib and Fenebrutinib failed to reach their respective IC90 values.

- **Pharmacokinetic characteristics**: The exposure of Tolebrutinib in CSF was 4.8 ng/mL, exceeding its IC90 value, indicating that it can effectively inhibit BTK activity in the CNS. In contrast, the CSF exposures of Evobrutinib and Fenebrutinib were 3.2 ng/mL and 12.9 ng/mL respectively, neither of which reached their respective IC90 values.

### Significance of the study

This study emphasizes the potential of Tolebrutinib as a new - generation drug for the treatment of multiple sclerosis, especially in terms of penetrating the blood - brain barrier and effectively inhibiting BTK in the CNS. This is of great significance for solving the problem that existing treatment methods cannot completely prevent the progression of the disease, especially for patient groups that are insensitive to traditional immunomodulatory therapies.